wherein X is C(O)R1 or H, and R1 is a saturated C $_{18}$ carbon hydrogen residue and R2 is a saturated or unsaturated C $_{2}$ -C $_{18}$ carbon hydrogen residue.

the D- or L-tryptophanyl-ester or its N-acyl derivative is selected from the group consisting of tryptophanoctyl-ester, tryptophandodecyl-ester, tryptophanstearyl-ester, tryptophanoctyl-ester, tryptophanoleyl-ester, N-acetyl-tryptophanoctyl-ester, N-acetyl-tryptophanodecyl-ester, N-acetyl-tryptophanoctyl-ester, N-acetyl-tryptophanoleyl-ester, N-acetyl-tryptophanoctyl-ester, N-acetyl-tryptophanoleyl-ester, N-dodecanoyl-tryptophanoctyl-ester, N-dodecanoyl-tryptophandodecyl-ester, N-dodecanoyl-tryptophanoleyl-ester, N-dodecanoyl-tryptophanoleyl-ester, N-acetyl-tryptophanethyl-ester, N-hexoyl-tryptophanethyl-ester, N-octoyl-tryptophanethyl-ester, N-dodecanoyl-tryptophanethyl-ester, N-dodecanoyl-tryptophanethyl-ester, N-dodecanoyl-tryptophanethyl-ester, N-palmitoyl-tryptophanethyl-ester and N-oleoyl-tryptophanethyl-ester.

17. (Added) The pharmaceutical composition according to claim 12, wherein the D- or L-tryptophanethyl-ester or its N-acetyl derivative is selected from the group consisting of tryptophanoctyl-ester, N-oleoy -tryptophanethyl-ester and N-dodecanoyl-tryptophanethyl-ester.

REMARKS

Applicants have amended the specification to make reference to a priority claim to International Application No. PCT/EP99/06819, filed on September 15, 1999.

Applicants have canceled claim 13 without prejudice and added claims 14-17.

Support for claim 14 may be found, *inter alia*, on page 6, lines 4-10. Support for claims 15-17

may be found, *inter alia*, in claim 12 as originally filed. Applicants have amended claims 1-12 to improve their form. Specifically, applicants have amended the format of claims 1-11 to recite "a method for treating or preventing a disease" instead of a "use" of the compounds in this invention. Applicants have also amended claims 2-12 to add dependency from added claim 14. Applicants have amended claim 12 to recite the article "A" before the first word in the claim. A marked-up copy of the amended claims is attached hereto as Appendix A.

Claims 1-12 and 14-17 are now pending. None of the amendments add new matter.

Entry of the amendments is requested.

Respectfully submitted,

James F. Haley, Jr. (Reg. No. 27,794)

Attorney for Applicants

Elinor K. Shin (Reg. No. 43,117)

Agent for Applicants

c/o FISH & NEAVE (Customer No. 1473)

1251 Avenue of the Americas

New York, New York 10020-1104

Tel.: (212) 596-9000 Fax.: (212) 596-9090